News

G207 Fast Track Designation

Treovir announces today that G207 has been granted Fast Track Designation by the US FDA for treatment of recurrent high-grade gliomas in children. Fast Track Designation will provide Treovir the benefit of more frequent meetings with...

Treovir Announces G207 Acquisition

Treovir announces today that it has executed an Asset Acquisition Agreement with Aettis, Inc. to acquire 100% of the assets relating to G207, a clinical stage product currently in clinical trials to treat pediatric brain...

G207 Orphan Designation

Treovir announces that G207 has been awarded Orphan Drug designation by the US FDA for treatment of medulloblastoma (DRU-2019-824) and primitive neuroectodermal brain tumor (PNET) (DRU-2019-6922). Together with the previous orphan designation in glioblastoma (2002-1552),...